Johanne I Weberpals Selected Research

Therapeutics

1/2021	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
1/2021	Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
10/2020	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
1/2020	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
10/2017	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
10/2011	Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johanne I Weberpals Research Topics

Disease

12	Neoplasms (Cancer) 01/2021 - 07/2008
10	Ovarian Neoplasms (Ovarian Cancer) 12/2021 - 08/2011
7	Carcinoma (Carcinomatosis) 10/2021 - 10/2017
3	Disease Progression 01/2021 - 01/2020
2	Diarrhea 01/2020 - 12/2018
2	Ovarian Epithelial Carcinoma 05/2015 - 07/2008
2	Squamous Cell Carcinoma of Head and Neck 11/2014 - 08/2012
1	Neutropenia 01/2021
1	Thrombocytopenia (Thrombopenia) 01/2021
1	Anemia 01/2020
1	Vomiting 01/2020
1	Proteinuria 12/2018
1	Hypertension (High Blood Pressure) 12/2018
1	Neoplasm Metastasis (Metastasis) 10/2017
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 08/2017
1	Vesicular Stomatitis 08/2012
1	Breast Neoplasms (Breast Cancer) 08/2011

Drug/Important Bio-Agent (IBA)

11	PlatinumIBA 12/2021 - 08/2011
6	rucaparibIBA 10/2021 - 10/2017
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2011
3	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2020 - 10/2011
3	Proteins (Proteins, Gene)FDA Link 05/2015 - 07/2008
2	Paclitaxel (Taxol)FDA LinkGeneric 12/2021 - 01/2020
2	Pharmaceutical PreparationsIBA 01/2021 - 10/2011
2	adavosertibIBA 01/2021 - 01/2020
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2020 - 10/2011
2	DNA (Deoxyribonucleic Acid)IBA 08/2017 - 01/2010
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2016 - 11/2014
2	Cisplatin (Platino)FDA LinkGeneric 08/2011 - 01/2010
2	BRCA1 ProteinIBA 08/2011 - 07/2008
1	olaparibIBA 12/2021
1	Etoposide (VP 16)FDA LinkGeneric 12/2021
1	B7-H1 AntigenIBA 01/2021
1	Gemcitabine FDA Link 01/2021
1	Poly Adenosine Diphosphate RiboseIBA 01/2021
1	chemotactic factor inactivatorIBA 01/2020
1	Carboplatin (JM8)FDA LinkGeneric 01/2020
1	ENMD 2076IBA 12/2018
1	AntigensIBA 10/2017
1	Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA 08/2017
1	Rosuvastatin Calcium (Crestor)FDA Link 03/2016
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 05/2015
1	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 05/2015
1	Monensin (Coban)IBA 11/2014
1	Hydroxymethylglutaryl CoA Reductases (HMG CoA Reductase)IBA 11/2014
1	Anti-Bacterial Agents (Antibiotics)IBA 11/2014
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2014
1	InterferonsIBA 08/2012
1	Histone Deacetylase InhibitorsIBA 08/2011
1	Messenger RNA (mRNA)IBA 08/2011
1	Vorinostat FDA Link 08/2011
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 07/2008

Therapy/Procedure

8	Drug Therapy (Chemotherapy) 01/2021 - 08/2011
6	Therapeutics 01/2021 - 10/2011
1	Oncolytic Virotherapy 08/2012